Company Overview and News

11
Friday’s Biggest Winners and Losers in the S&P 500

2018-06-15 247wallst
June 15, 2018: The S&P 500 closed down 0.1% at 2,779.41. The DJIA closed down 0.4% at 25,088.05. Separately, the Nasdaq was down 0.2% at 7,746.38.
NDAQ DISCA MRO

217
Nasdaq Composite Closes at Record High: 5 Top-Ranked Picks

2018-06-15 zacks
On Jun 14, the tech-heavy Nasdaq Composite index scaled a fresh high at closing. Yesterday’s rally can be attributed to strong showing by media, telecom and tech stocks fueled by market anticipation of mega merger deals. This also highlights the gradual fading of investors’ apprehensions regarding the trade and geopolitical issues, which was the primary reason behind severe market volatility in the last three months.
FOX DISCB DISCA TWX DISCK TWC CHTR CMTL SPG.PRJ MU MLNX SPG NTAP FOXA DIS DISC

248
With or Without Time Warner, AT&T Stock Isn't Worth Buying | InvestorPlace

2018-06-13 investorplace
The acquisition of Time Warner Inc (NYSE:TWX) by AT&T Inc. (NYSE:T) appears to be a go. And the approval of the AT&T-TWX merger, announced Tuesday afternoon, already is reverberating through the market.
DISCB DISCA CCV TWX CCZ DISCK AMCX VIAB AET CMCSK DIS DISC CBS VIA FOX TMUSP CBS.A TMUS CMCSA TWC CBS.WD S T CCV.CL CPV FOXA ESRX

75
Discovery Is Undervalued - Cramer's Lightning Round (6/11/18)

2018-06-12 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, June 11.
VIA ADT DISCA ADPVV VIAB ADP LB ISRG ABMD

29
Corporate round-up: Aegon Life appoints Saba Adil as Chief Operating Officer

2018-06-11 moneycontrol
Aegon Life Insurance has appointed Saba Adil as the new chief operating officer, effective May 1.
HYUO DISCB DISCA HYUP DISCK HYUD DISC

51
Discovery Communications (DISCA) Down 5.7% Since Earnings Report: Can It Rebound?

2018-06-07 zacks
A month has gone by since the last earnings report for Discovery Communications, Inc. (DISCA - Free Report) . Shares have lost about 5.7% in that time frame.
SNI DISCB DISCA ENL DISCK CRAI ENDP DISC

87
Palatin shares up 9% premarket

2018-06-04 marketwatch
Palatin Technologies Inc. shares surged 9% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has accepted the new drug application for bremelanotide, a treatment for female sexual desire disorder. The NDA was filed by Amag Pharmaceuticals Inc. , Palatin's exclusive North America licensee, in March. The goal date for completion of the review is March 23, 2019. If approved, bremelanotide would be the first and only treatment for hypoactive sexual desire disorder (HSDD) in pre-menopausal women.
VRTX AMAG DISCB DISCA PTN NYTAB DISCK FOSL DISC

122
How Facebook Let Gadgets Tap Your Data: DealBook Briefing - The New York Times

2018-06-04 nytimes
The technology giant struck data-sharing partnerships with at least 60 device makers — including Amazon, Apple, BlackBerry, Microsoft and Samsung — over the last decade. The company claimed that those deals were supposed to make it easier for people to use Facebook before its app was widely available on smartphones. But an NYT investigation found that the deals provided wide-ranging access to user data, and that many arrangements still exist, even though Facebook said that it had cut such off third-party access in 2015.
DISCB DISCA PANW NYTAB DISCK SNAP DISC

26
Orange aiming to merge video arm with Altice Studio - Le Figaro

2018-05-31 reuters
PARIS (Reuters) - Orange (ORAN.PA), France’s biggest telecoms operator, is looking to merge its Orange Cinema Series (OCS) arm with Altice Studio (ATCA.AS) to create a new business big enough to challenge the likes of Netflix (NFLX.O), Le Figaro newspaper reported.
DISCB DISCA DISCK DISC

257
Zero Cost Of Capital

2018-05-31 seekingalpha
Today’s strange occurrence has been called a “zero cost of capital” and it rhymes with what happened in 1999-2000.
DISCB DISCA WBA NFLX DISCK TGT JWN AMZN TSLA RNG NTNX DISC ETSY

104
Zero Cost Of Capital – ValueWalk Premium

2018-05-30 valuewalkpremium
Massive investor popularity can produce some pretty strange circumstances in the U.S. stock market. Mark Twain said, “History doesn’t repeat itself, but it rhymes!” Today’s strange occurrence has been called a “zero cost of capital” and it rhymes with what happened in 1999-2000. This is a phrase coined by NYU Business Professor, Scott Galloway, in his effort to explain the moat surrounding today’s tech darlings.
DISCB DISCA RNG DISCK NTNX DISC ETSY

132
Solo: A Star Wars Story Bomb Highlights Risks to Walt Disney Co Stock | InvestorPlace

2018-05-29 investorplace
It’s probably unfair to Walt Disney Co (NYSE:DIS) to call Solo: A Star Wars Story a bomb. After all, the movie generated $103 million in its opening weekend — the fourth-best showing so far this year. And when including an estimated $65 million in overseas receipts, Solo at least looks set to be a profitable film for Disney.
CBS MAT HAS DISCB AMCX DISCA CBS.A CPV DISCK CBS.WD DIS DISC

8
Rising Interest Rates & Discovery Inc.

2018-05-29 seekingalpha
Sentiment reset itself and now it’s acting as a neutral to bullish tailwind for the market.
DISCA

62
Bull Of The Day: Generac (GNRC)

2018-05-23 zacks
Generac (GNRC - Free Report) is a Zacks Rank #1 (Strong Buy) following a solid beat and raise quarter. Let's take a look a the recent numbers and how they have helped the stock reach the best Zacks Rank. Today, GNRC is the Bull of the Day.
TAPOF TPOYY DISCB DISCA GNRC DISCK TAP CSIQ TTD AKAM DISC

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 25470F104